{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:24:16Z","timestamp":1794410656840,"version":"4.9.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00415-022-11341-2","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T09:03:27Z","timestamp":1663578207000},"page":"413-422","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis"],"prefix":"10.1007","volume":"270","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6849-9667","authenticated-orcid":false,"given":"Ma\u00eblle","family":"Chappuis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Bajeux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Wiertlewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Laplaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Le Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Edan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Kerbrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,16]]},"reference":[{"issue":"8","key":"11341_CR1","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1177\/1352458519848090","volume":"26","author":"K Ahrweiller","year":"2020","unstructured":"Ahrweiller K, Rousseau C, Le Page E, Bajeux E, Leray E, Michel L et al (2020) Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis. Mult Scler 26(8):924\u2013935. https:\/\/doi.org\/10.1177\/1352458519848090","journal-title":"Mult Scler"},{"issue":"12","key":"11341_CR2","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1136\/jnnp.2008.145805","volume":"79","author":"H Tremlett","year":"2008","unstructured":"Tremlett H, Zhao Y, Joseph J, Devonshire V, UBCMS Clinic Neurologists (2008) Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatry 79(12):1368\u20131374. https:\/\/doi.org\/10.1136\/jnnp.2008.145805","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11341_CR3","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3389\/fneur.2017.00577","volume":"8","author":"AM Weideman","year":"2017","unstructured":"Weideman AM, Tapia-Maltos MA, Johnson K, Greenwood M, Bielekova B (2017) Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments. Front Neurol 8:577. https:\/\/doi.org\/10.3389\/fneur.2017.00577","journal-title":"Front Neurol"},{"issue":"11","key":"11341_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s11910-017-0800-8","volume":"17","author":"E Grebenciucova","year":"2017","unstructured":"Grebenciucova E, Pruitt A (2017) Infections in patients receiving multiple sclerosis disease-modifying therapies. Curr Neurol Neurosci Rep 17(11):88. https:\/\/doi.org\/10.1007\/s11910-017-0800-8","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"2","key":"11341_CR5","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","volume":"77","author":"G Luna","year":"2020","unstructured":"Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M et al (2020) Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol 77(2):184\u2013191. https:\/\/doi.org\/10.1001\/jamaneurol.2019.3365","journal-title":"JAMA Neurol"},{"issue":"2","key":"11341_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/1352458511435105","volume":"18","author":"PS S\u00f8rensen","year":"2012","unstructured":"S\u00f8rensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E et al (2012) Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 18(2):143\u2013152. https:\/\/doi.org\/10.1177\/1352458511435105","journal-title":"Mult Scler"},{"issue":"5","key":"11341_CR7","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/ana.24651","volume":"87","author":"P Alping","year":"2020","unstructured":"Alping P, Askling J, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M et al (2020) Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Ann Neurol 87(5):688\u2013699. https:\/\/doi.org\/10.1002\/ana.24651","journal-title":"Ann Neurol"},{"issue":"2","key":"11341_CR8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D et al (2018) ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 24(2):96\u2013120","journal-title":"Mult Scler"},{"issue":"10","key":"11341_CR9","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1136\/jnnp-2016-313760","volume":"87","author":"I Kister","year":"2016","unstructured":"Kister I, Spelman T, Alroughani R, Lechner-Scott J, Duquette P, Grand\u2019Maison F et al (2016) Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. J Neurol Neurosurg Psychiatry 87(10):1133\u20131137. https:\/\/doi.org\/10.1136\/jnnp-2016-313760","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"11341_CR10","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1007\/s00415-020-10029-9","volume":"267","author":"A-L Kaminsky","year":"2020","unstructured":"Kaminsky A-L, Omorou AY, Soudant M, Pittion-Vouyovitch S, Michaud M, Anxionnat R et al (2020) Discontinuation of disease-modifying treatments for multiple sclerosis in patients aged over 50 with disease Inactivity. J Neurol 267(12):3518\u20133527. https:\/\/doi.org\/10.1007\/s00415-020-10029-9","journal-title":"J Neurol"},{"key":"11341_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101468","volume":"37","author":"A Juto","year":"2020","unstructured":"Juto A, Fink K, Al Nimer F, Piehl F (2020) Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity. Mult Scler Relat Disord 37:101468. https:\/\/doi.org\/10.1016\/j.msard.2019.101468","journal-title":"Mult Scler Relat Disord"},{"key":"11341_CR12","doi-asserted-by":"publisher","first-page":"175628641983780","DOI":"10.1177\/1756286419837809","volume":"12","author":"L Prosperini","year":"2019","unstructured":"Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S (2019) Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther Adv Neurol Disord 12:1756286419837809. https:\/\/doi.org\/10.1177\/1756286419837809","journal-title":"Ther Adv Neurol Disord"},{"issue":"1\u20132","key":"11341_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jns.2011.05.043","volume":"308","author":"A Kerbrat","year":"2011","unstructured":"Kerbrat A, Le Page E, Leray E, Anani T, Coustans M, Desormeaux C et al (2011) Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients. J Neurol Sci 308(1\u20132):98\u2013102. https:\/\/doi.org\/10.1016\/j.jns.2011.05.043","journal-title":"J Neurol Sci"},{"issue":"7","key":"11341_CR14","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1001\/jamaneurol.2016.0826","volume":"73","author":"SE Hatcher","year":"2016","unstructured":"Hatcher SE, Waubant E, Nourbakhsh B, Crabtree-Hartman E, Graves JS (2016) Rebound Syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol 73(7):790\u2013794. https:\/\/doi.org\/10.1001\/jamaneurol.2016.0826","journal-title":"JAMA Neurol"},{"issue":"8","key":"11341_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jns.2011.05.043","volume":"55","author":"C Confavreux","year":"1992","unstructured":"Confavreux C, Compston DA, Hommes OR, McDonald WI, Thompson AJ (1992) EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 55(8):671\u2013676. https:\/\/doi.org\/10.1016\/j.jns.2011.05.043","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"11341_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2","journal-title":"Lancet Neurol"},{"issue":"5","key":"11341_CR17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1177\/1352458518765656","volume":"25","author":"LH Hua","year":"2019","unstructured":"Hua LH, Fan TH, Conway D, Thompson N, Kinzy TG (2019) Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60. Mult Scler 25(5):699\u2013708. https:\/\/doi.org\/10.1177\/1352458518765656","journal-title":"Mult Scler"},{"issue":"2","key":"11341_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/ene.13181","volume":"24","author":"J Bonenfant","year":"2017","unstructured":"Bonenfant J, Bajeux E, Deburghgraeve V, Le Page E, Edan G, Kerbrat A (2017) Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis? Eur J Neurol 24(2):237\u2013244. https:\/\/doi.org\/10.1111\/ene.13181","journal-title":"Eur J Neurol"},{"key":"11341_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.msard.2019.07.021","volume":"35","author":"H Yano","year":"2019","unstructured":"Yano H, Gonzalez C, Healy BC, Glanz BI, Weiner HL, Chitnis T (2019) Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes. Mult Scler Relat Disord 35:119\u2013127. https:\/\/doi.org\/10.1016\/j.msard.2019.07.021","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"11341_CR20","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1177\/1352458516675751","volume":"23","author":"G Bsteh","year":"2017","unstructured":"Bsteh G, Feige J, Ehling R, Auer M, Hegen H, Di Pauli F et al (2017) Discontinuation of disease-modifying therapies in multiple sclerosis\u2014clinical outcome and prognostic factors. Mult Scler 23(9):1241\u20131248. https:\/\/doi.org\/10.1177\/1352458516675751","journal-title":"Mult Scler"},{"key":"11341_CR21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jns.2018.06.001","volume":"391","author":"I Kister","year":"2018","unstructured":"Kister I, Spelman T, Patti F, Duquette P, Trojano M, Izquierdo G et al (2018) Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. J Neurol Sci 391:72\u201376. https:\/\/doi.org\/10.1016\/j.jns.2018.06.001","journal-title":"J Neurol Sci"},{"key":"11341_CR22","doi-asserted-by":"publisher","unstructured":"Fox et al. (2014) MS disease activity in RESTORE A randomized 24-we.pdf. https:\/\/doi.org\/10.1212\/WNL.0000000000000355","DOI":"10.1212\/WNL.0000000000000355"},{"issue":"3","key":"11341_CR23","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/ana.22074","volume":"68","author":"J Killestein","year":"2010","unstructured":"Killestein J, Vennegoor A, Strijbis EM, Seewann A, van Oosten BW, Uitdehaag BMJ et al (2010) Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol 68(3):392\u2013395. https:\/\/doi.org\/10.1002\/ana.22074","journal-title":"Ann Neurol"},{"issue":"22","key":"11341_CR24","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1212\/WNL.0b013e31821e7c8a","volume":"76","author":"PW O\u2019Connor","year":"2011","unstructured":"O\u2019Connor PW, Goodman A, Kappos L, Lublin FD, Miller DH, Polman C et al (2011) Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 76(22):1858\u20131865. https:\/\/doi.org\/10.1212\/WNL.0b013e31821e7c8a","journal-title":"Neurology"},{"key":"11341_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.msard.2017.01.009","volume":"12","author":"J Fagius","year":"2017","unstructured":"Fagius J, Feresiadou A, Larsson E-M, Burman J (2017) Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients. First line drugs vs natalizumab. Mult Scler Relat Disord 12:82\u201387. https:\/\/doi.org\/10.1016\/j.msard.2017.01.009","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"11341_CR26","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1111\/ene.13694","volume":"25","author":"J Frau","year":"2018","unstructured":"Frau J, Sormani MP, Signori A, Realmuto S, Baroncini D, Annovazzi P et al (2018) Clinical activity after fingolimod cessation: disease reactivation or rebound? Eur J Neurol 25(10):1270\u20131275. https:\/\/doi.org\/10.1111\/ene.13694","journal-title":"Eur J Neurol"},{"key":"11341_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102918","volume":"51","author":"V Pantazou","year":"2021","unstructured":"Pantazou V, Pot C, Du Pasquier R, Le Goff G, Th\u00e9audin M (2021) Recurrence of disease activity after fingolimod discontinuation in older patients previously stable on treatment. Mult Scler Relat Disord 51:102918. https:\/\/doi.org\/10.1016\/j.msard.2021.102918","journal-title":"Mult Scler Relat Disord"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11341-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-11341-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11341-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T17:20:19Z","timestamp":1672852819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-11341-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,16]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["11341"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-11341-2","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,16]]},"assertion":[{"value":"13 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors did not receive support from any organization for the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}